Fig. 7.

Proposed tumor interaction with DOTAP enantiomers. In vitro (R)- and (S)-DOTAP show little difference in stimulating BMDC, shown by the size of the straight arrows. Due to an unknown interaction between the immune system and the tumor, the presence of a tumor in the in vivo system amplified the difference between (R)- and (S)-DOTAP reflected by the size of the ribbon arrows. The distinction between the two formulations is further amplified via talk back from the tumor to the immune system